Clinical Trial

Oliceridine-Propofol Dose for Gastroscope Insertion in Obese Patients

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find the right dose of two medications, oliceridine and propofol, when used together for sedation in patients with obesity undergoing a painless gastroscope procedure. Currently, standard sedation methods using other opioids can sometimes cause breathing problems, especially in patients with obesity. Oliceridine is a newer medication that may provide good pain relief with a lower risk of these side effects. However, the best dose of propofol when combined with oliceridine for this specific patient group is not yet clear. This study will enroll patients with obesity (BMI ≥ 28 kg/m²) who are scheduled for a routine painless gastroscopy. Participants will receive the study medications during their procedure, and the medical team will carefully monitor their vital signs and sedation level. The study aims to find the most effective and safe dose combination to help guide future clinical practice.
Trial Details
NCT Number NCT07759778
Lead Sponsor Lu Yi
Conditions Obesity, Gastrointestinal Endoscopy
Enrollment 80 participants
Start Date 2026-08
Primary Completion 2027-02 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-12